Astrotech Corporation (ASTC) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Astrotech Corporation (NASDAQ: ASTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $4.71 (-2.69% 1D, market cap $10.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ASTC ranks #872 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), ASTC carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 47.5%, and ROIC of -35.0%. By comparison, BNGO (Bionano Genomics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M) and EYPT (EyePoint Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M). Among the 5-stock peer group, ASTC leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).
Per ASTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001001907), Astrotech Corporation generated $1.0M in revenue (-41.2% YoY), -$13.8M in net income, and -$13.8M in free cash flow against $19.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 35 (NEUTRAL RANGE)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ASTC currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.40) and Max Pain ($4.95) forces dealer call-delta covering toward $72.29.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Astrotech Corporation (ASTC) dropped -2.69% to $4.71, trading at 4% of its 52-week range ($1.92 – $68.85). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
Investing.com Nigeria report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
The proposed project, Astrotech Vertical Solar Array Maturation (AVSAM), would advance critical elements of the Astrotech Mobile Power System (AMPS) for potential future lunar surface use.The proposal targets maturation
Gainers Republic Power Group (NASDAQ:RPGL) stock moved upwards by 55.5% to $24.09 during Thursday's regular session. The company's market cap stands at $44.9 million. Alpha Modus Holdings (NASDAQ:AMOD) shares
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -41.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ASTC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ASTC. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Astrotech Corporation (ASTC) ranks #872 by composite RQD confidence (28/100, grade E) and #889 by equity capitalization ($10.2M). Within this direct 5-issuer industry benchmark cohort, ASTC leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. RPID currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with ASTC at 28/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ASTC
ACTIVE
Astrotech Corporation | E | 28/100 | — | 47.5% | -35.0% | -2.69% | $10.2M | Benchmark Subject |
| BNGO Bionano Genomics Inc. | E | 29/100 | — | 46.3% | -35.0% | +0.87% | $16.1M | /bngo-vs-astc → |
| EYPT EyePoint Inc. | E | 26/100 | — | — | -35.0% | +7.58% | $30.0M | /eypt-vs-astc → |
| PRPO Precipio Inc. | E | 30/100 | — | 44.2% | -7.9% | -1.71% | $32.4M | /prpo-vs-astc → |
| RPID Rapid Micro Biosystems Inc. (Class A) | E | 34/100 | — | — | -35.0% | -4.50% | $36.9M | /rpid-vs-astc → |
In its most recent audited fiscal period (FY2025, filed 2025-06-30), Astrotech Corporation (ASTC) reported GAAP revenue of $1.0M (-41.2% vs. FY2024 revenue of $1.7M , and +33.3% cumulative change since FY2023) , GAAP net income of -$13.8M, operating cash flow of -$13.0M, and free cash flow of -$13.8M (-33.8% YoY). On the balance sheet, ASTC closed FY2025 with $19.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $1.0M | -$13.8M | -$13.0M | -$13.8M | $19.7M | — |
| FY2024 (FY) | 2024-06-30 | $1.7M | -$11.7M | -$9.7M | -$10.3M | $31.0M | — |
| FY2023 (FY) | 2023-06-30 | $750.0K | -$9.6M | -$7.6M | -$7.6M | — | — |
As of 2026-11-03, Astrotech Corporation (NASDAQ: ASTC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $4.71 (-2.69% 1D, market cap $10.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ASTC ranks #872 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), ASTC carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 47.5%, and ROIC of -35.0%. By comparison, BNGO (Bionano Genomics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M) and EYPT (EyePoint Inc.) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $30.0M). Among the 5-stock peer group, ASTC leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).
Per ASTC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001001907), Astrotech Corporation generated $1.0M in revenue (-41.2% YoY), -$13.8M in net income, and -$13.8M in free cash flow against $19.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
ASTC last traded at $4.71 (-2.69% on volume of 31,223 shares), positioning the stock -26.41% below its 50-day simple moving average ($6.40) and -34.76% below its 200-day simple moving average ($7.22). Across its 52-week range of $1.92 to $68.85, ASTC sits at the 4.2% percentile with a 14-day RSI of 35.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.12 to $5.30).
Astrotech Corporation (ASTC) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.71 (-2.69% 1D, market capitalization $10.2M).
Astrotech Corporation (ASTC) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry. Gross margin is reported at 47.5%, while operating and net margins are both reported at -60%.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Astrotech Corporation (ASTC) reported $1.0M in annual revenue (up from $1.7M in FY2024, -41.2% YoY) and -$13.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($750.0K revenue, -$9.6M net income) through FY2025, ASTC scaled operating cash flow to -$13.0M and free cash flow to -$13.8M, backed by $19.7M in total assets against $0 in total debt.
The only sector-level context provided is the Health Care sector and Biotechnology: Laboratory Analytical Instruments industry classification. A prospective investor should watch whether the NASA-related lunar infrastructure proposal translates into revenue, since the source does not establish any link between that activity and the reported health-care industry classification.
Real-time company headlines, analyst actions, and sector developments for Astrotech Corporation (ASTC) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
Investing.com Nigeria report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering Astrotech Corporation (ASTC) market action, institutional positioning, and fundamental catalysts.
The proposed project, Astrotech Vertical Solar Array Maturation (AVSAM), would advance critical elements of the Astrotech Mobile Power System (AMPS) for potential future lunar surface use.The proposal targets maturation
Gainers Republic Power Group (NASDAQ:RPGL) stock moved upwards by 55.5% to $24.09 during Thursday's regular session. The company's market cap stands at $44.9 million. Alpha Modus Holdings (NASDAQ:AMOD) shares
Recent news flow includes a NASA NextSTEP-3 lunar power infrastructure proposal, a potential new revenue avenue not reflected in the reported financials.. When you look under the hood at ASTC, Fundamental Cash Engine is 6/20 with 47.5% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $68.85. My 12M target is $5.57.
@SiliconVal_Bull Agree on the RQD 28/100 quality, though with 1.0 beta I'm scaling in with half-size at $4.84 and keeping dry powder in case we test $4.50.
Fading this rally in ASTC at $4.84. Operating losses widened every year from -$11.1M to -$14.7M while revenue fell to $1.0M, and the RQD cash-engine pillar scored 6/20.. With a beta of 1.0 and the stock sitting at $4.84 (52-wk range $1.92–$68.85), the easy multiple expansion is already priced in.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: